1,397 Shares in Eli Lilly and Company $LLY Bought by Stonebridge Financial Group LLC MO

Stonebridge Financial Group LLC MO acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 1,397 shares of the company’s stock, valued at approximately $1,502,000. Eli Lilly and Company makes up 1.3% of Stonebridge Financial Group LLC MO’s holdings, making the stock its 18th largest holding.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bridgewealth Advisory Group LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $264,000. Summit Wealth Group LLC Co. boosted its position in shares of Eli Lilly and Company by 12.9% during the 4th quarter. Summit Wealth Group LLC Co. now owns 1,938 shares of the company’s stock valued at $2,083,000 after acquiring an additional 221 shares during the last quarter. Legacy Financial Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.7% during the 4th quarter. Legacy Financial Advisors Inc. now owns 3,149 shares of the company’s stock valued at $3,384,000 after acquiring an additional 141 shares during the last quarter. Madison Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 3.5% during the fourth quarter. Madison Asset Management LLC now owns 60,914 shares of the company’s stock worth $65,463,000 after purchasing an additional 2,058 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. grew its holdings in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 2,980 shares of the company’s stock worth $3,203,000 after purchasing an additional 10 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s new phase 3 obesity data suggest Foundayo and lower-dose Zepbound can preserve weight-loss results, strengthening confidence in its obesity franchise and future growth. Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
• Positive Sentiment: Coverage highlighting Lilly’s strategy to expand beyond tirzepatide with next-generation obesity drugs, including an oral pill and retatrutide, may reassure investors that the company is protecting its leadership position. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
• Positive Sentiment: Additional long-term data for Omvoh in ulcerative colitis adds another proof point for Lilly’s non-obesity pipeline and supports the broader growth story. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
• Neutral Sentiment: Lilly is celebrating its 150th anniversary with various company, community, and leadership-profile stories, but these are mostly reputational and unlikely to move the stock much on their own. Lilly CEO David Ricks keeps eye on future while company celebrates history
• Neutral Sentiment: Reuters reported Lilly launched its Alzheimer’s drug in India, a positive commercial development, but the immediate financial impact may be limited given the market’s focus on obesity growth. Eli Lilly launches Alzheimer’s drug Donanemab in India
• Negative Sentiment: Rival GLP-1 developers and new obesity entrants, including Kailera Therapeutics, add competitive pressure and show that Lilly’s market will remain highly contested. This Weight-Loss Drug Challenger Could Follow Eli Lilly’s Playbook: Analyst
• Negative Sentiment: Reports that Lilly paused an obesity awareness campaign in India after regulatory notices could be a modest headwind, though it does not appear to be a major earnings issue. Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,014.93 on Thursday. The company has a market capitalization of $955.80 billion, a price-to-earnings ratio of 36.05, a PEG ratio of 1.08 and a beta of 0.48. The business has a 50 day moving average of $939.87 and a 200 day moving average of $995.67. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LLY shares. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Rothschild & Co Redburn lifted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,218.33.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.